Pushing the limits of targeted therapy in chronic myeloid leukaemia.

Article Details

Citation
Copy to clipboard

O'Hare T, Zabriskie MS, Eiring AM, Deininger MW

Pushing the limits of targeted therapy in chronic myeloid leukaemia.

Nat Rev Cancer. 2012 Jul 24;12(8):513-26. doi: 10.1038/nrc3317.

PubMed ID
22825216 [ View in PubMed
]
Abstract

Tyrosine kinase inhibitor (TKI) therapy targeting the BCR-ABL1 kinase is effective against chronic myeloid leukaemia (CML), but is not curative for most patients. Minimal residual disease (MRD) is thought to reside in TKI-insensitive leukaemia stem cells (LSCs) that are not fully addicted to BCR-ABL1. Recent conceptual advances in both CML biology and therapeutic intervention have increased the potential for the elimination of CML cells, including LSCs, through simultaneous inhibition of BCR-ABL1 and other newly identified, crucial targets.

DrugBank Data that Cites this Article

Drugs